Specific glioblastoma multiforme prognostic-subtype distinctions based on DNA methylation patterns
文献类型：期刊论文
| 作者 | Ma, Huihui2,3; Zhao, Chenggang2,3; Zhao, Zhiyang2,3; Hu, Lizhu2,3; Ye, Fang1 ; Wang, Hongzhi1,3; Fang, Zhiyou1,3; Wu, Yuejin2,4; Chen, Xueran1,3
|
| 刊名 | CANCER GENE THERAPY
 |
| 出版日期 | 2020-09-01 |
| 卷号 | 27 |
| ISSN号 | 0929-1903 |
| DOI | 10.1038/s41417-019-0142-6 |
| 通讯作者 | Wu, Yuejin(yjwu@ipp.ac.cn) ; Chen, Xueran(xueranchen@cmpt.ac.cn) |
| 英文摘要 | DNA methylation is an important regulator of gene expression, and plays a significant role in carcinogenesis in the brain. Here, we explored specific prognosis-subtypes based on DNA methylation status using 138 Glioblastoma Multiforme (GBM) samples from The Cancer Genome Atlas (TCGA) database. The methylation profiles of 11,637 CpG sites that significantly correlated with survival in the training set were employed for consensus clustering. We identified three GBM molecular subtypes, and their survival curves were distinct from each other. Furthermore, ten feature CpG sites were obtained on conducting a weighted gene co-expression network analysis (WGCNA) of the CpG sites. We were able to classify the samples into high- and low-methylation groups, and classified the prognosis information of the samples after cluster analysis of the training set samples using the hierarchical clustering algorithm. Similar results were obtained in the test set and clinical GBM specimens. Finally, we found that a positive relationship existed between methylation level and sensitivity to temozolomide (or radiotherapy) or anti-migration ability of GBM cells. Taken together, these results suggest that the model constructed in this study could help explain the heterogeneity of previous molecular subgroups in GBM and can provide guidance to clinicians regarding the prognosis of GBM. |
| WOS关键词 | GENE-EXPRESSION ; CANCER ; HYPERMETHYLATION ; PROGRESSION ; BIOMARKERS ; CAPACITY ; MARKERS |
| WOS研究方向 | Biotechnology & Applied Microbiology ; Oncology ; Genetics & Heredity ; Research & Experimental Medicine |
| 语种 | 英语 |
| WOS记录号 | WOS:000569884000007 |
| 出版者 | NATURE PUBLISHING GROUP |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/104075]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Wu, Yuejin; Chen, Xueran |
| 作者单位 | 1.Chinese Acad Sci, Hefei Canc Hosp, Dept Mol Pathol, 350 Shushan Hu Rd, Hefei 230031, Anhui, Peoples R China 2.Univ Sci & Technol China, 96 Jin Zhai Rd, Hefei 230026, Anhui, Peoples R China 3.Chinese Acad Sci, Hefei Inst Phys Sci, Anhui Prov Key Lab Med Phys & Technol, Ctr Med Phys & Technol, 350 Shushan Hu Rd, Hefei 230031, Anhui, Peoples R China 4.Chinese Acad Sci, Hefei Inst Phys Sci, Inst Tech Biol Agr Engn, 350 Shushan Hu Rd, Hefei 230031, Anhui, Peoples R China |
| 推荐引用方式 GB/T 7714 | Ma, Huihui,Zhao, Chenggang,Zhao, Zhiyang,et al. Specific glioblastoma multiforme prognostic-subtype distinctions based on DNA methylation patterns[J]. CANCER GENE THERAPY,2020,27. |
| APA | Ma, Huihui.,Zhao, Chenggang.,Zhao, Zhiyang.,Hu, Lizhu.,Ye, Fang.,...&Chen, Xueran.(2020).Specific glioblastoma multiforme prognostic-subtype distinctions based on DNA methylation patterns.CANCER GENE THERAPY,27. |
| MLA | Ma, Huihui,et al."Specific glioblastoma multiforme prognostic-subtype distinctions based on DNA methylation patterns".CANCER GENE THERAPY 27(2020). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。